Practical considerations in development of solid dosage forms that contain cyclodextrin

Journal of Pharmaceutical Sciences

Volumn 96, Issue 7, 2007, Pages 1691-1707

  Miller, Lee A ^a   Carrier, Rebecca L ^b   Ahmed, Imran ^a  

^a PFIZER INC   (United States)

^b Northeastern University   (United States)

Author keywords

Absorption; Complexation; Cyclodextrins; Formulation; Solid dosage form

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ALPHA CYCLODEXTRIN; BETA CYCLODEXTRIN; CAVAMAX; CYCLODEXTRIN; DIAZEPAM; DODECYL SULFATE SODIUM; GAMMA CYCLODEXTRIN; GLIBENCLAMIDE; HYDROCORTISONE; INDOMETACIN; KLEPTOSE; METHYLCELLULOSE; PARACETAMOL; POLYMER; UNCLASSIFIED DRUG; VINBURNINE; WARFARIN; ZIPRASIDONE;

CIRCULAR DICHROISM; COMPLEX FORMATION; CRITICAL MICELLE CONCENTRATION; DECISION MAKING; DISSOLUTION; DOG; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG GRANULATION; DRUG MANUFACTURE; DRUG RESEARCH; DRUG SOLUBILITY; DRUG STABILITY; FREEZE DRYING; MICROSCOPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEAR OVERHAUSER EFFECT; PARTICLE SIZE; PH MEASUREMENT; PHYSICAL CHEMISTRY; REVIEW; SCANNING ELECTROCHEMICAL MICROSCOPY; SHEAR STRENGTH; SPRAY DRYING; TABLET COMPRESSION; THERMAL ANALYSIS;

EID: 34547226591     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20831     Document Type: Review

References (72)

1. Thompson DO. 1997. Cyclodextrins-enabling excipients: Their present and future use in pharmaceuticals. Crit Rev Ther Drug Carrier Syst 14:1-104.
2. Mosher G, Thompson D. 2002. Complexation and cyclodextrins. In: Swarbrick J, Boylan J, editors. Encyclopedia of pharmaceutical technology, 1st edition. New York: Marcel Dekkar. pp 531-558.
3. Duchene D, Glomot F, Vaution C. 1987. Pharmaceutical applications of cyclodextrins. In: Duchene D, editor. Cyclodextrins and their industrial uses, 1st edition. Paris, France: Editions de Sante. pp 214-230.
4. Szejtli J. 1994. Medicinal applications of cyclodextrins. Med Res Rev 14:353-386.
5. m-P-cyclodextrin as both a solubilizing and an osmotic pump agent. J Control Release 58:29-38.
6. Okimoto K, Rajewski R, Stella V. 1998. Design and evaluation of an osmotic pump tablet for prednisolone, a poorly water soluble drug using SBECD. Pharm Res 15:1562-1568.
7. Zannou EA, Streng WH, Stella VJ. 2001. Osmotic properties of sulfobutylether and hydroxypropyl cyclodextrins. Pharm Res 18:1226-1231.
8. Gan Y, Pan W, Wei M, Zhang R. 2002. Cyclodextrin complex osmotic tablet for glipizide delivery. Drug Dev Ind Pharm 28:1015-1021.
9. Uekama K, Otagiri M. 1987. Cyclodextrins in drug carrier systems. CRC Crit Rev Ther Drug Carrier Syst 3:1-40.
10. Connors KA. 1997. The stability of cyclodextrin complexes in solution. Chem Rev 97:1325-1357.
11. Rajewski RA. 1996. Pharmaceutical applications of cyclodextrins. 2. in vivo drug delivery. J Pharm Sci 85:1142-1169.
12. Burnette RR, Connors KA. 2000. Statistical properties of thermodynamic quantities for cyclodextrin complex formation. J Pharm Sci 89:1389-1394.
13. Connors KA. 1995. Population characteristics of cyclodextrin complex stabilities in aqueous solution. J Pharm Sci 84:843-848.
14. Rao VM, Stella VJ. 2003. When can cyclodextrins be considered for solubilization purposes? J Pharm Sci 92:927-932.
15. Lantz JR, Schwartz JB. 1990. Mixing. In: Lieberman HA, Lachman L, Schwartz JB, editors. Pharmaceutical dosage forms: tablets, 2nd edition. New York: Marcel-Dekker, Inc. pp 1-70.
16. Islam MS, Narurkar MM. 1991. The effect of 2-hydroxypropyl-β- cyclodextrin on the solubility, stability, and dissolution rate of famotidine. Drug Dev Ind Pharm 17:1229-1239.
17. Lin SY, Kao YH. 1989. Studies on drug interaction in pharmaceutical formulations. Part XII. Solid particulates of drug-β-cyclodextrin inclusion complexes directly prepared by a spray-drying technique. Inter J Pharm 56:249-259.
18. Lin S-Z, Wouessidjewe D. 1991. Indomethacin and cyclodextrin complexes. Inter J Pharm 69:211-219.
19. Elkheshen SA, Ahmed SM, Al-Quadeib T. 2002. Inclusion complexes of piroxicam with β-cyclodextrin derivatives in comparison with the natural?β-cyclodextrin. Pharm Ind 64:708-715.
20. Koester LS, Ortega GG, Mayorga P, Bassani VL. 2004. Mathematical evaluation of in vitro release profiles of hydroxypropylmethylcellulose matrix tablets containing carbamazepine associated to β-cyclodextrin. Eur J Pharm Biopharm 58:177-179.
21. Savolainen J, Jarvinen K, Taipale H, Jarho P, Loftsson T, Jarvinen T. 1998. Co-administration of a water-soluble polymer increases the usefulness of cyclodextrins in solid oral dosage forms. Pharm Res 15:1696-1701.
22. m-β-cyclodextrin as a solubilizing agent. J Pharm Sci 90:807-816.
23. Cydex. 2004. ed.: info_cd@cydexinc.com.
24. Biddy D, Davies NA, Tucker IG. 2000. Mechanisms by which cyclodextrins modify drug release from polymeric drug delivery systems. Int J Pharm 197:1-11.
25. Higuchi T, Connors KA. 1965. Phase solubility techniques. In: Reilly CN, editor. Advances in analytical chemistry and instrumentation, 2nd edition. New York: Marcel-Dekker. pp 117-212.
26. Loftsson T, Masson M, Brewster ME. 2004. Self-association of cyclodextrins and cyclodextrin complexes. J Pharm Sci 93:1091-1099.
27. Zia V, Rajewski RA, Stella VJ. 2000. Thermodynamics of binding of neutral molecules to sulfobutyl ether β-cyclodextrins (SBE-β-CDs): The effect of total degree of substitution. Pharm Res 17:936-941.
28. Connors KA. 1987. Binding constants: The measurement of molecular complex stability, 1st edition. New York: Wiley-Interscience.
29. Higuchi T, Connors KA. 1965. Phase solubility techniques. In: Reilly CN, editor. Advances in analytical chemistry and instrumentation, 2nd edition. New York: Marcel-Dekker. pp 135-136.
30. Higuchi T, Connors KA. 1965. Phase solubility techniques. In: Reilly CN, editor. Advances in analytical chemistry and instrumentation, 2nd edition. New York: Marcel-Dekker. pp 138-139.
31. Roquette F. 2002. Technical bulletin on Kleptose?β-cyclodextrin and hydroxypropyl betacyclodextrins, ed. France: Roquette Freres.
32. Erden N, Celebi N. 1988. A study of the inclusion complex of naproxen with β-cyclodextrin. Int J Pharm 48:83-89.
33. Lin SY, Kao YH, Yang JC. 1988. Grinding effect on some pharmaceutical properties of drugs by adding β-cyclodextrin. Drug Dev Indust Pharm 14:99-118.
34. Darrouzet H. 1992. Practical considerations concerning the use of cyclodextrins as complexing agents. In: Hedges A, editor. Minutes of the Sixth International Symposium on cyclodextrins, 6th edition. Paris, France: Editions de Sante. pp 301-307.
35. Hirayama F. 1987. Methods of investigating and preparing inclusion compounds. In: Duchene D, editor. Cyclodextrin and their Industrial uses, 1st edition. Paris, France: Editions de Sante. 158 p.
36. Carli F, Chiesi P. 1991. Process for preparing piroxicam/cyclodextrin complexes, the products obtained and their pharmaceutical compositions. Eur Pat Appl, ed., Ep: (Chiesi Farmaceutici S.p.A., Italy). p 10.
37. Cavallari C, Abertini B, Gonzalez-Rodriguez ML, Rodriguez L. 2002. Improved dissolution behavior of steam-granulated piroxicam. Eur J Pharm Biopharm 54:65-73.
38. Rey L. 1999. Glimpses into the realm of freeze-drying: Classical issues and new ventures. In: Rey L, May J, editors. Freeze-drying and lyophilization of pharmaceutical and biological products, 2nd edition. New York: Marcel-Dekker. pp 1-30.
39. Masters K. 1991. Spray drying handbook, 4th edition. Essex, London: Longman Scientific and Technical.
40. Sebille B, Thuaud N, Piquion J, Behar N. 1987. Determination of association constants of beta-cyclodextrin and beta-cyclodextrin-bearing polymers with drugs by high-performance liquid chromatography. J Chromatogr 409:61-69.
41. Bekers O, Uijtendaal EV, Beijnen JH, Bult A, Underberg WJM. 1991. Cyclodextrins in the pharmaceutical field. Drug Dev Ind Pharm 17:1503-1549.
42. Van Hees T, Piel G, de Hassonville SH, Evrard B, Delattre L. 2002. Determination of the free/included piroxicam ratio in cyclodextrin complexes: Comparison between UV spectrophotometry and differential scanning calorimetry. Eur J Pharm Sci 15:347-353.
43. Martin A. 1993. Physical Pharmacy, 4th edition. Baltimore, MD: Williams and Wilkins.
44. Giordano F, Bruni G, Bettinetti GP. 1992. Solid-state microcalorimetry on drug-cyclodextrin binary systems. J Thermal Anal 38:2683-2691.
45. Hedges A, Shieh W. 1991. Complexation in modified cyclodextrin compared with unmodified cyclodextrin. In: Duchene D, editor. New Trends in Cyclodextrins and Derivatives, ed. Paris, France: Editions de Sante. 301 p.
46. Ghorab MK, Adeyeye MC. 2001. Elucidation of solution state complexation in wet-granulated oven-dried ibuprofen and β-cyclodextrin: FT-IR and 1H-NMR studies. Pharma Dev Technol 6:315-324.
47. Kim Y, Oksanen DA, Massefski W Jr, Blake JF, Duffy EM, Chrunyk B. 1998. Inclusion complexation of ziprasidone mesylate with beta-cyclodextrin sulfobutyl ether. J Pharm Sci 87:1560-1567.
48. 1H-NMR contribution as the ultimate tool for the study of drug/cyclodextrin interaction. STP Pharm Sci 9:267-271.
49. Bettinetti G, Melani F, Mura P, Monnanni R, Giordano F. 1991. Carbon-13 nuclear magnetic resonance study of naproxen interaction with cyclodextrins in solution. J Pharm Sci 80:1162-1170.
50. Mullarney MP, Hancock BC, Carlson GT, Ladipo DD, Langdon BA. 2003. The powder flow and compact mechanical properties of sucrose and three high-intensity sweeteners used in chewable tablets. Int J Pharm 257:227-236.
51. Hancock BC, Carlson GT, Ladipo DD, Langdon BA, Mullarney MP. 2001. The powder flow and compact mechanical properties of two recently developed matrix-forming polymers. J Pharm Pharmacol 53:1193-1199.
52. Tasic LJ, Pintye-Hodi K, Szabo-Revesz P. 1997. Evaluation of the compression behavior of paracetamol tablets produced by dispersion in β-cyclodextrin. Part I: Scanning electron microscopic study of tablets. J Inclus Phenom Mol Recog Chem 28:299-314.
53. Langdon BA, Carlson GT. 2000. Personal communication, ed.
54. Munoz-Ruiz A, Paronen P. 1997. Particle and powder properties of cyclodextrins. Int J Pharm 148:33-39.
55. Shangraw RF, Pande GS, Gala P. 1992. Characterization of the tableting properties of β-cyclodextrin and the effects of processing variables on inclusion complex formation, compactibility and dissolution. Drug Dev Ind Pharm 18:1831-1851.
56. Marini A, Berbenni V, Massarotti V, Mustarelli P, Riccardi R, Gazzaniga A, Giordano F, Bruni G, Villa M. 1993. Thermal study of water/β- cyclodextrin interactions. Solid State Ionics 63-65:358-362.
57. Hegde RP, Rhodes CT. 1985. Preparation of a phenytoin β-cyclodextrin complex and evaluation of a suspension and a tablet dosage form prepared from the complex. Pharm Acta Helv 60:53-57.
58. Pande GS, Shangraw RF. 1994. Characterization of β-cyclodextrin for direct compression tableting. Int J Pharm 101:71-80.
59. Saleh SI. 1993. β-Cyclodextrin as a direct compression excipient compared to conventional ones. J Pharm Belg 48:371-377.
60. Ghorab MK, Adeyeye MC. 2001. Enhancement of ibuprofen dissolution via wet granulation with b-cyclodextrin. Pharm Dev Technol 6:305-314.
61. Tsai T, Wu JS, Ho HO, Sheu MT. 1998. Modification of physical characteristics of microcrystalline cellulose by codrying with beta-cyclodextrins. J Pharm Sci 87:117-122.
62. Szejtli J. 1991. Cyclodextrins in drug formulations: Part II. Pharm Technol August:24-38.
63. Arima H, Yunomae K, Miyake K, Irie T, Hirayama F, Uekama K. 2001. Comparative studies of the enhancing effects of cyclodextrins on the solubilty and oral bioavailability of Tacrolimus in rats. J Pharm Res 90:690-701.
64. Evrard B, Chiap P, DeTullio P, Ghalmi F, Piel G, Van Hees T, Crommen J, Losson B, Delattre L. 2002. Oral bioavailabilty in sheep of albendazole from a suspension and from a solution containing hydroxypropyl-β-cycldextrin. J Control Release 85:45-50.
65. Reddy DN, Singh UV, Pandey S, Udupa N. 1992. Evaluation of piroxicam oral and transdermal preparations. Indian J Pharm Sci 54:152-154.
66. Loftsson T, Fridriksdottir H, Sigurdardottir AM. 1994. The effect of water-soluble polymer on drug cyclodextrin complexation. Int J Pharm 110:169.
67. Loftsson T, Gudmundsdottir TK, Fridriksdottir F. 1996. The influence of water-soluble polymers and pH on hydroxypropyl-b-cyclodextrin complexation of drugs. Drug Dev Ind Pharm 22:401.
68. Loftsson T, Masson M. 2004. The effects of water-soluble polymers on cyclodextrins and cyclodextrin solubilization of drugs. J Drug Del Sci Tech 14:35-43.
69. Teresa M, Paola M. 2001. Effect of water-soluble polymers on naproxen complexation wth natural and chemically modified beta-cyclodextrin. Drug Dev Ind Pharm 27:909-917.
70. Rekharsky MV, Inoue Y. 1998. Complexation thermodynamics of cyclodextrins. Chem Rev 98:1875.
71. Veiga M-D, Ahsan F. 1997. Study of surfactants/β-cyclodextrin interactions over mequitazine dissolution. Drug Dev Ind Pharm 23:721-725.
72. Giordano F, Gazzaniga A, Bettinetti GP, La Manna A. 1990. The influence of water content on the binding capacity of β-cyclodextrin. Int J Pharm 62:153-156.